CEO Q&A with Neil Crabb at Frontier IP Group PLC (LON:FIPP)

Frontier IP Group PLC (LON:FIPP) Chief Executive Officer Neil Crabb caught up with DirectorsTalk for an exclusive interview to discuss Tarsis Technology’s collaboration with a world-leading crop protection company.

 

Q1: We’ve seen your latest announcement, can you tell us more about Tarsis Technology, what it is and exactly what was announced?

A1: It’s a spin-out from the University of Cambridge, it’s developing an advanced materials technology to enable the delivery of active ingredients in a more precise and controlled way.
The spin-out in fact we own 18% of, and the deal that was announced is a collaboration with one of the world’s leading manufacturers of crop protection products where it will use Tarsis materials to research the potential to deliver existing pesticides and fungicides in a more precise and controlled way. If that proof of concept is shown, then we would hope that would lead to a full commercial agreement and that they might actually introduce the products directly to the market.

 

Q2: So, what Tarsis’ materials technology?

A2: So, it’s got a patent-pending process for essentially locking ingredients into a category of particles known as metal organic frameworks and these metal organic frameworks are some of the most porous material that are known. Essentially, they have a large number of holes within them where you’ve got polymer lignin’s joined by metals and you can put an active ingredient such as a pesticide into those holes.

The Tarsis team have some access to a large library of those materials, the best understanding in the world of the materials that are available, but there’s another piece that needs to be solved here which the Tarsis team have addressed. Once you’ve got the active ingredient inside the metal-organic framework, you need to be able to trap it so it doesn’t just leak out and they are doing that. Essentially, you can get the active in there and once it’s in there they lock in place and they control the release or how it responds to some kind of trigger so that you can only get it to be active when you want it to be active and in a controlled fashion. So, there’s lots of markets there, people want to be able to take an active and control its function and when it performs its role rather than just having it generally around environmentally.

 

Q3: What is the role of Frontier IP with Tarsis Technology?

A3: Our role is essentially to not as a core development of the science of course, because that’s driven by the academic team, but to handle the negotiations with commercial partners. So, in this case, to work in getting the collaboration agreement in place and then the backend supply agreements to make sure that the project can actually be delivered. That’s essentially a large part of what we do as a business is that we take interesting science and then make it capable of being translated across to industry partners.

If you look elsewhere in our portfolio, you would find that we’ve got companies like Nandi Proteins which is developing proteins to allow reduction of sugar, fat and additives in processed food and again, we’ve got a scientific team driving the development of the technology but equally, we would be handling the interface with industry to get industry players working on it.

We’ve got a company called Alusid where the team there have a novel idea for how you can combine glass and ceramics to produce a recycled but high-quality building product and again, we’ve worked with supply chain and channels to market to enable scale-up.

There are also a couple of other firms recently that have been added to the portfolio. So, we’ve had Cambridge Material Testing Solutions, which is developing methods to measure material stresses and strains more swiftly and that has a lot of applications in industries such as nuclear, aerospace and gas. We’ve then got a company called PoreXpert, which we’ve had for a while, who’s software is already being used to look at how, for example, you look at graphite in nuclear reactors but we’re looking at other applications and other industries that can be applied in.

So, across the board, Frontier IP’s role is to take interesting technology but then find out how we can get that engaged with industry partners and that’s the piece where essentially Frontier IP steps in and within that we’ve done that in each case for a significant stake in the portfolio company that’s exploiting the technology.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Frontier IP Group Plc

    More articles like this

    Frontier IP Group Plc

    Animal Lovers and Zoonotic Diseases: 5 Things to Know

    Zoonotic diseases, or zoonoses, are on the rise. That may first bring to mind exotic diseases like Ebola, but the reality is that many zoonotic infections happen closer to home, often during everyday activities. In 2018,

    Frontier IP Group Plc

    AI-based initiatives catalyzing immunotherapy in 2018

    Artificial intelligence (AI) has been dynamically changing the field of drug discovery in several areas, including immunotherapy, oncotherapy, neurological disease, and many more. Described here is an ensemble of the initiatives in place to advance the field of

    Frontier IP Group Plc

    Frontier IP Group Plc appoint N+1 Singer as sole broker

    Frontier IP Group PLC (LON:FIPP), a specialist in commercialising university intellectual property, today announced the appointment of Nplus1 Singer Advisory LLP as the Group’s sole broker with immediate effect. Allenby Capital Limited remains the Group’s Nominated Adviser.

    Frontier IP Group Plc

    Britain’s university spinout sector is thriving

    They are among Britain’s greatest national treasures and a powerful engine of ideas and innovation for the nation’s booming technology industry. But how good are UK universities at commercialising the research and expertise which springs from

    Frontier IP Group Plc

    Exscientia CEO explains how AI is transforming drug discovery

    In recent decades a strange confluence has formed in the pharmaceutical industry. A range of powerful technologies have brought enormous new capabilities to the sector, productivity has been simultaneously declining. Deloitte’s Centre for Health Solutions estimates that projected returns on investment

    Frontier IP Group Plc

    How technology is revolutionising the healthcare industry

    A technology revolution is transforming the healthcare industry, changing everything from how patients are diagnosed and treated to our battle against some of the world’s most serious diseases. It’s a revolution fuelled by new sources of

    Frontier IP Group Plc

    Artificial Intelligence will Revolutionise Drug Discovery

    New technologies are making their way into the healthcare industry and healthcare providers are already experimenting with advances such as smart pill technology, 3D-printed medication, and mobile apps. But probably the biggest potential lies in artificial intelligence

    Frontier IP Group Plc

    Rallybio forges joint venture with U.K. tech firm

    A Farmington biotech startup formed by a trio of former top Alexion executives said it is working on drug discovery with an artificial intelligence company in the United Kingdom. Rallybio, focused on rare diseases, has not yet publicly

    Frontier IP Group Plc

    What is leptospirosis and how can it harm us and our pets?

    Recently reported cases of the often fatal bacterial infection leptospirosis in dogs in Sydney have raised the issue of animal diseases that also affect humans. This zoonotic disease is spread by rats and other rodents. However, this

    Frontier IP Group Plc

    The Robot Uprising Is Here

    The robot uprising is inevitable. Take the world’s first raspberry-picking robot, an autonomous machine that’s in development by Fieldwork Robotics at the University of Plymouth in the UK. This fruit-picking Terminator, so to speak, was developed for

    Frontier IP Group Plc

    The UK’s 50 Most Disruptive Companies Revealed

    After receiving applications from a wide range of early stage and more established companies from across industries, the initial list was whittled down to 100 by D/SRUPTION. The list was then submitted to an expert judging

    Frontier IP Group Plc

    Artificial intelligence in the world of drug discovery

    Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the

    Frontier IP Group Plc

    11 diseases which can cause infection

    Illnesses that can pass from animals to humans are known as zoonotic. They’re surprisingly common: More than six out of every 10 known infectious diseases in people are actually contracted from animals, according to the CDC.